Abstract
: The risk of drug-drug interactions (DDIs) is elevated in aging people living with HIV (PLWH) because of highly prevalent age-related comorbidities leading to more comedications. To investigate the impact of aging on DDI magnitudes between comedications (amlodipine, atorvastatin, rosuvastatin) and boosted darunavir, we conducted a clinical trial in aging PLWH aged at least 55 years. DDI magnitudes were comparable with those reported in young individuals supporting that the clinical management of DDIs in aging PLWH can be similar.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aged
-
Aged, 80 and over
-
Aging*
-
Amlodipine / adverse effects
-
Amlodipine / therapeutic use
-
Anti-Retroviral Agents / therapeutic use
-
Antiretroviral Therapy, Highly Active*
-
Atorvastatin / adverse effects
-
Atorvastatin / therapeutic use
-
Cardiovascular Agents / adverse effects
-
Cardiovascular Agents / therapeutic use*
-
Cardiovascular Diseases / drug therapy*
-
Cardiovascular Diseases / epidemiology
-
Darunavir / adverse effects
-
Darunavir / therapeutic use
-
Drug Interactions*
-
Female
-
HIV Infections / drug therapy*
-
HIV Infections / epidemiology
-
Heterocyclic Compounds, 3-Ring / adverse effects
-
Heterocyclic Compounds, 3-Ring / therapeutic use
-
Humans
-
Male
-
Middle Aged
-
Oxazines / adverse effects
-
Oxazines / therapeutic use
-
Piperazines / adverse effects
-
Piperazines / therapeutic use
-
Pyridones / adverse effects
-
Pyridones / therapeutic use
-
Rosuvastatin Calcium / adverse effects
-
Rosuvastatin Calcium / therapeutic use
-
Treatment Outcome
Substances
-
Anti-Retroviral Agents
-
Cardiovascular Agents
-
Heterocyclic Compounds, 3-Ring
-
Oxazines
-
Piperazines
-
Pyridones
-
Amlodipine
-
Rosuvastatin Calcium
-
Atorvastatin
-
dolutegravir
-
Darunavir